IGF-1 LR3

IGF-1 LR3 is an 83-amino-acid recombinant analog of native human insulin-like growth factor 1 (IGF-1), developed in the early 1990s as a research tool for studying IGF-1 biology free of IGFBP interference. The molecule incorporates two modifications from the native 70-aa IGF-1 sequence: a 13-amino-acid N-terminal extension and substitution of the position 3 glutamic acid with arginine (Arg3). These changes dramatically reduce binding affinity for IGF-binding proteins (particularly IGFBP-3), increasing the free, bioactive peptide fraction by approximately 3-fold and extending plasma half-life from 12-15 minutes (native IGF-1) to 20-30 hours. The compound binds the IGF-1 receptor with full agonist activity comparable to native IGF-1, activating PI3K-AKT-mTOR signaling for protein synthesis and MAPK signaling for cell proliferation. Native IGF-1 (mecasermin, Increlex) is FDA-approved for severe primary IGF-1 deficiency. The LR3 variant has not undergone clinical trials and is not approved for any indication. The compound is used off-label in bodybuilding at 20-50 mcg subcutaneously daily. IGF-1 LR3 is WADA-prohibited under Section S2.

Background: IGF-1 Biology and the Need for Modified Analogs

Insulin-like growth factor 1 (IGF-1) is a 70-amino-acid peptide hormone primarily produced in the liver under growth hormone (GH) stimulation. It mediates most of GH's anabolic effects, including muscle protein synthesis, cell proliferation, and tissue growth. The IGF-1 axis includes:

• IGF-1 itself: 70-aa peptide, plasma half-life 12-15 minutes when free, several hours when IGFBP-bound
• IGF-binding proteins (IGFBPs 1-6): 6 distinct binding proteins that sequester circulating IGF-1
• IGFBP-3: the dominant binder, normally bound to >75% of circulating IGF-1
• Acid-labile subunit (ALS): forms ternary complex with IGFBP-3 and IGF-1, further extending circulating half-life
• IGF-1 receptor (IGF1R): the tyrosine kinase receptor mediating IGF-1 effects
• Insulin receptor (IR): cross-reactivity at high IGF-1 concentrations

The IGFBP system was a problem for early IGF-1 research: native recombinant IGF-1 administered subcutaneously was rapidly bound by IGFBPs, with most of the administered dose immediately sequestered and unavailable for receptor binding. This motivated the development of IGF-1 analogs with reduced IGFBP affinity, including LR3, Long [Arg3]IGF-1, and IGF-1 DES.

Development of IGF-1 LR3

The LR3 analog was developed by Francis and colleagues at the University of Adelaide in the early 1990s. The Francis 1992 Journal of Molecular Endocrinology paper characterized the design rationale and biological properties. The 13-aa N-terminal extension (Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu-Phe-Val-Asn-Gln) and the Glu3-to-Arg3 substitution were specifically engineered to:

• Reduce binding affinity for IGFBPs (particularly IGFBP-3 and IGFBP-5)
• Maintain full binding affinity at the IGF-1 receptor
• Extend plasma half-life through reduced IGFBP-mediated clearance
• Increase the bioactive free fraction of administered peptide

The result was an analog with approximately 3-fold higher biological potency in vivo than native IGF-1, and with a dramatically extended pharmacokinetic profile suitable for once-daily subcutaneous dosing.

The compound was originally intended for research use to study IGF-1 effects in animal models without IGFBP interference. It was never developed for human clinical use, and no clinical trials specifically evaluating IGF-1 LR3 have been completed.

Pharmacokinetics

• Plasma half-life: 20-30 hours after subcutaneous administration, compared to 12-15 minutes for unbound native IGF-1
• Bioavailability: subcutaneous bioavailability >70%, approximately 3x greater free-fraction bioavailability than native IGF-1
• Volume of distribution: similar to other peptide hormones, distributes systemically
• Metabolism: classical protein catabolism in liver and kidneys
• Tissue distribution: systemic, with effects on muscle, liver, bone, kidney, and other IGF1R-expressing tissues

The 20-30 hour half-life makes once-daily dosing pharmacologically reasonable. Longer dosing intervals would produce significant trough-to-peak variations.

Native IGF-1 (Mecasermin/Increlex): The FDA-Approved Precedent

Mecasermin (Increlex), the FDA-approved recombinant native IGF-1 from Tercica/Ipsen, provides the clinical evidence base for IGF-1 axis manipulation:

• FDA approval: 2005 for severe primary IGF-1 deficiency and growth hormone receptor mutations (Laron syndrome) in pediatric patients
• Indication restriction: limited to specific genetic conditions causing severe IGF-1 deficiency
• Dosing: 0.04-0.12 mg/kg subcutaneously twice daily
• Clinical efficacy: increased height velocity in IGF-1-deficient children
• Adverse effects: hypoglycemia (most common, dose-limiting), lymphoid tissue hypertrophy (tonsils, adenoids, spleen), intracranial hypertension, slipped capital femoral epiphysis, scoliosis progression, allergic reactions
• Boxed warning: not for use in children with closed growth plates

Mecasermin's adverse effect profile provides indirect evidence for IGF-1 LR3 safety concerns, though the modifications and off-label use context differ substantially.

Absence of LR3-Specific Clinical Trials

A defining characteristic of IGF-1 LR3 is the complete absence of published human clinical trials. PubMed and ClinicalTrials.gov searches identify:

• No Phase 1, 2, or 3 clinical trials of IGF-1 LR3 in humans
• No human pharmacokinetic studies of the LR3 variant specifically
• No safety studies in human populations
• No efficacy studies for any indication

The available data come from:

• Animal studies (rat, mouse, sheep, cattle) on muscle anabolism, growth, tissue effects
• Cell culture studies on IGF-1 receptor signaling
• Indirect inference from clinical experience with mecasermin and from native IGF-1 physiology
• Anecdotal bodybuilding-community reports (uncontrolled, subject to selection bias)

This is a significant evidence gap given the extent of off-label bodybuilding use. Patients using IGF-1 LR3 do so without LR3-specific safety or efficacy validation.

Off-Label Bodybuilding Use

The dominant current use of IGF-1 LR3 is off-label in bodybuilding contexts:

Typical protocols:

• 20-50 mcg subcutaneously, once daily (morning or pre-workout)
• Some protocols: split dose (10-25 mcg twice daily)
• Some protocols: site-specific intramuscular injection for targeted effect (the targeting rationale is largely undermined by the 20-30 hour half-life producing systemic distribution)
• Cycle length 4-6 weeks
• Often stacked with MGF/PEG-MGF, GH or GH-releasing peptides, anabolic steroids

Goals reported by users:

• Increased muscle protein synthesis
• Enhanced recovery between training sessions
• Improved nutrient partitioning toward muscle
• Hyperplasia (new muscle fiber formation) claims, though clinical evidence is lacking
• Reduced body fat (through nutrient partitioning)

Evidence quality: anecdotal, uncontrolled, almost always confounded by concurrent compound use (testosterone, growth hormone, multiple peptides).

Regulatory Status

• FDA: Not approved. No marketing applications submitted for the LR3 variant. Available only as a research chemical
• EMA: Not approved
• WADA: Prohibited at all times in and out of competition under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). WADA testing methods can detect IGF-1 and its analogs
• Research-chemical channels: principal access route. Quality, identity verification, and purity vary substantially by supplier

IGF-1 LR3's mechanism is identical to native IGF-1 at the receptor level: full agonist activity at the IGF-1 receptor (IGF1R). The modifications affect pharmacokinetics and bioavailability without altering the molecular biology of receptor binding or downstream signaling.

IGF-1 Receptor Activation

The IGF-1 receptor is a tyrosine kinase receptor with structural and functional similarities to the insulin receptor. IGF-1 binding triggers:

• Receptor dimerization and autophosphorylation
• Recruitment and activation of insulin receptor substrate (IRS) proteins
• PI3K-AKT-mTOR pathway activation: principal pathway for protein synthesis. mTORC1 phosphorylates 4E-BP1 and S6K1, increasing translation initiation and elongation
• RAS-MAPK pathway activation: principal pathway for cell proliferation and survival
• GLUT4 translocation and glucose uptake: insulin-like metabolic effects at higher IGF-1 concentrations
• Inhibition of proteasomal protein degradation: contribution to net protein accretion

The principal anabolic effect in skeletal muscle is increased protein synthesis through mTORC1 activation, combined with reduced proteolysis.

Differences from Native IGF-1

The N-terminal extension and Arg3 substitution affect only IGFBP interactions, not IGF1R binding:

• Native IGF-1: binds IGFBPs with high affinity. In circulation, >95% is bound to IGFBPs and only the small free fraction can engage IGF1R. The IGFBP-bound pool serves as a slow-release reservoir.
• IGF-1 LR3: dramatically reduced IGFBP binding. Most administered peptide remains free and bioactive. The result is higher peak free-fraction concentrations and longer-sustained receptor engagement.

The clinical consequence is that IGF-1 LR3 produces effective receptor activation at much lower administered doses than native IGF-1 would require.

Receptor Cross-Reactivity

At high concentrations, IGF-1 LR3 can cross-react with the insulin receptor (IR), producing insulin-like metabolic effects including hypoglycemia. This is the principal acute safety concern with IGF-1 administration. The Arg3 substitution does not significantly alter insulin receptor cross-reactivity.

Tissue Effects

Skeletal muscle:

• Increased protein synthesis through mTORC1 activation
• Reduced protein degradation
• Satellite cell support (less directly than MGF)
• Improved nutrient partitioning toward muscle protein deposition

Connective tissue:

• Tendon and ligament fibroblast activation
• Collagen synthesis support
• Cartilage support (chondrocyte effects)

Liver:

• Reduced GH/IGF-1 axis feedback (through negative feedback at the hypothalamus and pituitary)
• Indirect effects on hepatic metabolism

Bone:

• Osteoblast activation
• Bone mineral density support

Kidney:

• Glomerular filtration rate increases
• Renal hypertrophy with chronic high-dose use

Adipose tissue:

• Reduced lipolysis at high concentrations
• Generally favors muscle protein deposition over fat storage

Cancer and Mitogenic Signaling

IGF-1 receptor signaling is implicated in proliferation of many cancer types, particularly breast, prostate, colorectal, and lung cancers (Pollak 2008 Nature Reviews Cancer review). Chronic systemic IGF-1 receptor activation raises theoretical concerns about cancer initiation and progression, though the human evidence for clinically relevant cancer risk from short-term IGF-1 LR3 use is limited.

Effects in preclinical models (animal studies):

• Substantial increase in muscle protein synthesis and mass (rats, sheep, cattle, mice)
• Increased growth rate in juvenile animals
• Improved nitrogen retention
• Effects on bone, kidney, liver as expected from IGF-1 biology
• Cancer model effects: increased tumor growth in some animal cancer models (mitogenic concerns)

Effects in clinical experience with mecasermin (native IGF-1) (indirect evidence relevant to IGF-1 LR3):

• Increased height velocity in IGF-1-deficient children
• Hypoglycemia (dose-limiting)
• Lymphoid tissue hypertrophy
• Slipped capital femoral epiphysis (growth plate effect)
• Intracranial hypertension
• Scoliosis progression in predisposed patients

Effects in off-label bodybuilding use (anecdotal, uncontrolled):

• Reported increased muscle mass beyond exercise alone
• Reported enhanced recovery
• Reported improved nutrient partitioning (more nutrients to muscle, less to fat)
• Reported hyperplasia claims (no human evidence)
• Reported hypoglycemia at higher doses
• Reported "pumps" (transient localized fluid effects)
• Highly variable individual response
• Confounded by concurrent use of testosterone, GH, other peptides in typical bodybuilding stacks

Effects in human clinical trials of IGF-1 LR3 specifically: none. No published human clinical trials of the LR3 variant exist.

Honest evidence framing: IGF-1 LR3 has well-characterized biology in animal models and clear mechanistic plausibility based on the extensive native IGF-1 literature. The pharmacokinetic improvements over native IGF-1 are real and pharmacologically sensible. However, the absence of LR3-specific human clinical trials means safety and efficacy in humans rest on indirect inference from mecasermin clinical data and anecdotal bodybuilding reports. The cancer signaling concerns from chronic IGF-1 receptor activation are real and pharmacologically expected, though the practical risk from short-term off-label use has not been quantified. Mitogenic risk in individuals with pre-existing undiagnosed cancers is the principal serious theoretical concern.

Important note: IGF-1 LR3 has no FDA-approved dosing protocol and no published human clinical dosing data specific to the LR3 variant. All doses described below come from bodybuilding-community practice.

Common off-label bodybuilding protocols:

• Standard daily protocol: 20-50 mcg subcutaneously, once daily (morning or pre-workout)
• Split-dose protocol: 10-25 mcg twice daily
• Higher-dose protocol: 50-80 mcg daily (diminishing returns, increased hypoglycemia risk)
• Site-specific intramuscular protocol: 5-10 mcg per injection site, multiple sites for targeted muscle group focus (rationale undermined by 20-30 hour systemic half-life)
• Cycle length: typically 4 weeks. Some protocols extend to 6 weeks. Continuous use beyond 6 weeks increases concern about IGFBP-3 suppression and feedback effects on the GH/IGF-1 axis

Routes:

• Subcutaneous: most common, abdominal injection sites
• Intramuscular: occasional, for site-specific theoretical targeting
• Pre-workout timing: some protocols dose 15-30 minutes pre-training
• Post-workout timing: some protocols dose post-workout to coincide with anabolic window

Reconstitution and storage:

• Lyophilized peptide reconstituted with bacteriostatic water or 0.9% sodium chloride
• Reconstitution acidic (some preparations use weak acetic acid)
• Refrigeration after reconstitution (2-8°C)
• Stability: typically 2-4 weeks at 2-8°C after reconstitution
• Lyophilized powder stable at -20°C for extended periods

Stacking considerations:

• Commonly stacked with PEG-MGF or native MGF for combined satellite cell activation and protein synthesis
• Commonly stacked with GHRPs (ipamorelin, GHRP-6, hexarelin) and GHRH analogs (CJC-1295)
• Combined with testosterone or AAS in steroid-using bodybuilding contexts
• Combined with insulin in some protocols (significant hypoglycemia risk)

Mecasermin (Increlex) FDA-approved dosing for comparison:

• 0.04-0.12 mg/kg subcutaneously twice daily for severe primary IGF-1 deficiency
• Initial dose 0.04 mg/kg, titrated up based on tolerance
• Administered shortly before or after a meal to reduce hypoglycemia
• Pediatric indication only

Special populations:

• Pregnancy: contraindicated. No safety data. Pediatric mecasermin labeling extrapolation suggests significant risk
• Breastfeeding: avoid
• Pediatric: not appropriate outside specific FDA-approved mecasermin indications. Use in growing humans is contraindicated due to growth plate concerns
• Active or history of malignancy: contraindicated due to mitogenic concerns
• Diabetic retinopathy: relative contraindication due to IGF-1 axis effects on retinal vasculature
• Severe insulin sensitivity disorders: caution
• Athletes subject to WADA testing: prohibited at all times

Adverse effects observed in mecasermin (native IGF-1) FDA-approved use (provides indirect evidence for IGF-1 LR3 safety profile):

• Hypoglycemia: most common and dose-limiting. Particularly with fasting or inadequate caloric intake. Acute risk of severe hypoglycemia
• Lymphoid tissue hypertrophy: tonsils, adenoids, spleen. Can cause airway obstruction in children
• Intracranial hypertension (pseudotumor cerebri): rare but serious
• Slipped capital femoral epiphysis: growth plate effect in growing children
• Scoliosis progression: in patients with pre-existing scoliosis
• Injection-site reactions: lipohypertrophy, lipoatrophy, pain
• Allergic reactions: rare but reported

Adverse effects reported in off-label IGF-1 LR3 bodybuilding use (anecdotal):

• Hypoglycemia (most common acute issue)
• Injection-site reactions
• Headache
• Mild gut discomfort
• Joint and muscle discomfort
• Sleepiness or fatigue
• Edema and fluid retention

Theoretical and class-effect concerns:

• Cancer initiation and progression: chronic IGF-1 receptor activation is implicated in multiple cancer types. The practical risk from off-label use is unquantified but real. Patients with undiagnosed pre-malignant lesions could theoretically experience accelerated progression
• Acromegaly-like effects: chronic high-dose IGF-1 axis activation can produce features overlapping with acromegaly (organ growth, soft tissue changes, joint discomfort)
• Cardiac hypertrophy: chronic IGF-1 receptor activation in cardiac tissue can produce pathological hypertrophy
• IGFBP-3 suppression: chronic exogenous IGF-1 administration suppresses endogenous IGFBP-3 production, potentially altering the IGF-1 axis balance
• GH/IGF-1 axis feedback suppression: chronic exogenous IGF-1 suppresses endogenous GH secretion through negative feedback
• Insulin resistance: chronic high IGF-1 exposure can promote insulin resistance
• Mitogenic effects on non-target tissues: kidney, spleen, liver, lymphoid tissues
• Research-chemical quality variability: significant practical concern. Identity, purity, endotoxin content, and proper folding vary substantially between suppliers. No FDA quality oversight

Contraindications and cautions:

• Active malignancy or significant history of malignancy
• Diabetic retinopathy
• Pregnancy and breastfeeding
• Pediatric and adolescent use (open growth plates)
• Hypersensitivity to the peptide
• Closed growth plates context (specifically per mecasermin label for the FDA-approved indication)
• Severe hypoglycemia history
• Athletes subject to anti-doping testing

Drug interactions:

• Insulin: significant additive hypoglycemia risk. Stacking is dangerous
• Oral hypoglycemics: additive hypoglycemia risk
• Growth hormone and GHRPs: synergistic IGF-1 axis activation
• Corticosteroids: opposing effects on muscle protein synthesis (corticosteroid catabolism vs IGF-1 anabolism)
• Anabolic-androgenic steroids: additive anabolic effects through different mechanisms

IGF-1 LR3 sits at the center of the IGF-1 family peptides used in off-label bodybuilding contexts. Its closest comparators:

• IGF-1 DES: truncated 67-aa IGF-1 lacking the first 3 N-terminal residues. Higher IGF1R affinity (5-10x) but short half-life. Used for site-specific local effects rather than systemic. Different practical profile than LR3
• MGF (Mechano Growth Factor): IGF-1Ec splice variant, 24-aa C-terminal E-peptide. Different mechanism (satellite cell activation through non-IGF1R pathway). Half-life 5-7 minutes
• PEG-MGF: pegylated MGF with 24-72 hour half-life. Same mechanism as native MGF. Often stacked with IGF-1 LR3 for combined satellite cell activation and protein synthesis
• Mecasermin (Increlex): FDA-approved recombinant native IGF-1. Pediatric severe primary IGF-1 deficiency indication. Provides the principal clinical evidence base for IGF-1 axis manipulation, with documented adverse effect profile

Common stacks circulating in bodybuilding contexts:

• IGF-1 LR3 + PEG-MGF: the classic anabolic stack. Rationale: PEG-MGF activates satellite cells, IGF-1 LR3 drives protein synthesis. No controlled data supports the specific protocol
• IGF-1 LR3 + GHRP-6/Ipamorelin + CJC-1295: combined GH elevation with direct IGF-1 axis activation. Common bodybuilding "GH stack"
• IGF-1 LR3 + Testosterone/AAS: combined anabolic effects through different mechanisms. Common in steroid-using contexts
• IGF-1 LR3 + Insulin: dangerous combination with significant hypoglycemia risk. Sometimes used in advanced bodybuilding contexts
• IGF-1 LR3 + IGF-1 DES: rarely combined. Different practical profiles (systemic vs site-specific)

Combinations to avoid or use with caution:

• Insulin: significant additive hypoglycemia risk. Combining IGF-1 LR3 with insulin carries acute danger
• Active malignancy: contraindicated. Theoretical and biologically plausible cancer concerns
• Pregnancy and breastfeeding: contraindicated. No safety data
• Pediatric and adolescent use: contraindicated. Growth plate effects
• Diabetic retinopathy: relative contraindication
• WADA-tested athletes: prohibited under S2

The most actionable framing of IGF-1 LR3 in 2026: this is a well-characterized recombinant IGF-1 analog with clear mechanistic biology and a real pharmacokinetic advantage over native IGF-1 (3x higher bioavailability, 20-30 hour half-life). The absence of LR3-specific human clinical trials means safety and efficacy in humans rest on indirect inference from mecasermin clinical experience and anecdotal bodybuilding reports. The principal serious safety concerns are hypoglycemia (acute, dose-limiting), mitogenic effects on pre-existing or undiagnosed cancers (theoretical but biologically real), and acromegaly-like effects with chronic high-dose use. Research-chemical quality is variable and difficult to verify. WADA prohibition is unambiguous. For users committed to using IGF-1 LR3, the practical considerations are reasonable dosing (20-50 mcg daily rather than escalating), cycle limitation (4-6 weeks with rest periods), avoidance of insulin co-administration, attention to hypoglycemia management (carbohydrate-containing meal proximate to dosing), and awareness that LR3-specific safety data does not exist. For users pursuing muscle hypertrophy without the LR3 risk profile, well-validated alternatives (progressive resistance training with adequate nutrition, and where medically appropriate, physician-supervised testosterone replacement) have substantially stronger evidence bases.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.